On May 8, 2019, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced first quarter 2019 financial results.  The company announced that it had entered into an agreement to acquire ATI-502, a topical treatment for the treatment of alopecia areata.  The agreement is subject to approval by the U.S. District Court for the Southern District of New York.  The agreement is subject to court approval by the court.  The agreement is subject to court approval.  According to the SEC's order, ATI-502 is a topical treatment that targets the production activity of TNF alpha, IL-1, IL-6 and IL-8.  ATI-502 is a topical treatment for the treatment of hair loss.  The agreement is subject to court approval and approval by the court.  The settlement is subject to court approval.  The SEC's continuing investigation is being conducted by David Gordon and Mark Dee of the Boston Regional Office.  The litigation will be led by Neal Walker.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using theÂ Investor.govÂ reportÂ toÂ check the background of anyone selling or offering an investment usingÂ Investor.govÂ Investor.govÂ toÂ check the background of people selling or offering investments inÂ Investor.gov.  The SEC appreciates the assistance of FINRA.